Intra Cellular Therapies, Inc. ITCI
We take great care to ensure that the data presented and summarized in this overview for Intra-Cellular Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITCI
View all-
Vanguard Group Inc Valley Forge, PA9.23MShares$620 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.08MShares$543 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$259 Million1.4% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.82MShares$190 Million3.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.48MShares$166 Million2.06% of portfolio
-
State Street Corp Boston, MA2.24MShares$151 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA2.07MShares$139 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.07MShares$139 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY1.76MShares$118 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY1.74MShares$117 Million0.1% of portfolio
Latest Institutional Activity in ITCI
Top Purchases
Top Sells
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Transactions at ITCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 24
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,020
+0.93%
|
$340,340
$17.22 P/Share
|
|
Mar 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
260
+0.26%
|
$17,940
$69.2 P/Share
|
|
Mar 31
2024
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
79
+0.81%
|
$5,451
$69.2 P/Share
|
|
Mar 20
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.77%
|
$360,000
$18.56 P/Share
|
|
Mar 11
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,712
-5.53%
|
$241,280
$65.97 P/Share
|
|
Mar 11
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,345
-7.04%
|
$477,425
$65.96 P/Share
|
|
Mar 11
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,345
-91.57%
|
$484,770
$66.26 P/Share
|
|
Mar 11
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,121
-95.16%
|
$667,986
$66.55 P/Share
|
|
Mar 11
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
20,565
-0.48%
|
$1,357,290
$66.21 P/Share
|
|
Mar 10
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+23.8%
|
-
|
|
Mar 10
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+16.55%
|
-
|
|
Mar 10
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+50.0%
|
-
|
|
Mar 10
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,121
+50.0%
|
$566,776
$56.73 P/Share
|
|
Mar 10
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,565
+1.88%
|
-
|
|
Mar 07
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,450
-15.44%
|
$425,700
$66.6 P/Share
|
|
Mar 07
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,132
-16.66%
|
$866,712
$66.66 P/Share
|
|
Mar 07
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,132
-99.16%
|
$866,712
$66.47 P/Share
|
|
Mar 07
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
13,132
-74.8%
|
$866,712
$66.6 P/Share
|
|
Mar 07
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,712
-1.88%
|
$2,686,992
$66.65 P/Share
|
|
Mar 06
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+36.73%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 820K shares |
|---|---|
| Grant, award, or other acquisition | 82.1K shares |
| Open market or private sale | 969K shares |
|---|